Keda Lu

Keda Luye is a Chinese biotechnology company focused on the discovery and development of novel small-molecule therapeutics for oncology and fibrotic diseases. The company's research primarily targets the STAT3 signaling pathway, exploring both phosphorylation inhibition and protein degradation strategies to treat various cancers. Keda Luye also investigates allosteric regulation of RNA-binding proteins like IGF2BP1 to modulate the tumor immune microenvironment. Additionally, the company is developing candidates for liver fibrosis by targeting the STAT3/Gli1 interaction. Its pipeline is largely in the pre-clinical stage, leveraging academic collaborations with institutions like the University of Science and Technology of China (USTC).